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Endocytic trafficking plays an important role in the regu-
lation of the epidermal growth factor receptor (EGFR). To
address if cellular kinases regulate EGFR internalization,
we used anisomycin, a potent activator of kinase cas-
cades in mammalian cells, especially the stress-acti-
vated mitogen-activated protein (MAP) kinase subtypes.
Here, we report that activation of p38 MAP kinase by
anisomycin is sufficient to induce internalization of
EGFR. Anisomycin and EGF employ different mechan-
isms to promote EGFR endocytosis as anisomycin-
induced internalization does not require tyrosine kinase
activity or ubiquitination of the receptor. In addition,
anisomycin treatment did not result in delivery and
degradation of EGFR at lysosomes. Incubation with a
specific inhibitor of p38, or depletion of endogenous
p38 by small interfering RNAs, abolished anisomycin-
induced internalization of EGFR while having no effect
on transferrin endocytosis, indicating that the effect of
p38 activation on EGFR endocytosis is specific.
Interestingly, inhibition of p38 activation also abolished
endocytosis of EGFR induced by UV radiation. Our
results reveal a novel role for p38 in the regulation of
EGFR endocytosis and suggest that stimulation of EGFR
internalization by p38 might represent a general mechan-
ism to prevent generation of proliferative or anti-
apoptotic signals under stress conditions.
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Growth factors and their transmembrane receptor tyro-
sine kinases (RTK) play important roles during embryonic
development and in the regulation of several cellular
processes including proliferation, survival, migration and
differentiation (1,2). Binding of growth factors to their
receptors activates a myriad of signaling pathways that
permit cells to respond to changes in the environment
(3). In many cases, the termination of these signaling
events is mediated by receptor internalization and degra-
dation (4). The epidermal growth factor receptor (EGFR) is
considered the prototypical member of the RTK family,
and its activation and trafficking have been exhaustively
characterized.Ligandbindingresultsinreceptordimerization
(5), activation and autophosphorylation of tyrosine residues
in the cytosolic tail (6). Phosphotyrosines serve then as
docking sites for the formation of protein networks that
mediate signaling as well as receptor endocytosis and
degradation (7). For example, autophosphorylation of spe-
cific tyrosines (Y992, Y1045, Y1068 and Y1086) is known
to recruit specific adaptors such as phospholipase Cg,
Casitas B-lineage lymphoma (Cbl) or growth factor recep-
tor binding protein 2 (Grb2).
Monoubiquitination of EGFR at multiple sites also seems
to play an important role in receptor down-regulation (8).
At the plasma membrane, receptor activation promotes
the recruitment of Cbl, an ubiquitin ligase that mediates
the ubiquitination of EGFR (9). Cbl can also interact with
the endocytic machinery, thus ensuring EGFR internaliza-
tion (10). At the endosomes, ubiquitin acts as a targeting
signal for degradation through interaction with the multi-
vesicular body-sorting machinery (11,12).
However, there are still several aspects of EGFR traffick-
ing that remain controversial. One is whether receptor
ubiquitination is required for internalization or if it just
plays a role in the delivery of the receptor to lysosomes.
It has been shown that chimerae consisting of the extra-
cellular and transmembrane domains of EGFR fused to a
single cytosolic exposed ubiquitin are constitutively inter-
nalized and degraded (8,12). However, other investigators
have reported that receptor ubiquitination is not sufficient
for EGFR endocytosis and that the role of Cbl is to link
EGFR to coated pits through the interaction of Cbl with
CIN85/endophilin complex (10,13). Recently, it has
been suggested that ubiquitin could determine the route
of EGFR internalization so that non-ubiquitinated EGFR
exclusively follows a clathrin-dependent pathway, while
ubiquitinated EGFR can enter into the cell through both
clathrin-coated pits and caveolae (14,15).
Another open question to be resolved is the role of
kinases in RTK internalization. As mentioned previously,
EGF stimulation activates different protein kinases that
participate in the transmission of many proliferative and
differentiative signals. These protein kinases include the
extracellular signal-regulated protein kinases (ERK) and
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686two mitogen-activated protein (MAP) kinases, the c-Jun
N-terminal kinase (JNK) (16) and the p38 MAP kinase
(p38) (17). There is growing evidence showing that kinase
activation does not only happen at the plasma membrane
but also at endosomes. Several EGFR downstream signal-
ing factors such as Grb2, Shc and mSOS localize to endo-
somes shortly after EGFR internalization (18,19). In
addition, robust MAP kinase activation requires the pre-
sence of active EGFR at endosomes (20,21) and seems to
promote cell survival (22,23). Therefore, trafficking of
EGFR regulates signal propagation and amplification
(24,25). Conversely, it has been suggested that signaling
can regulate EGFR internalization, as different proteins
implicated in signal transduction have been shown to
interact with the endocytosis sorting machinery (26,27).
Recently, Zerial’s group carried out high-throughput RNA
interference analysis to address the role of kinases in
endocytosis and showed that a large number of kinases
previously implicated in proliferation, growth and cell
adhesion also have a role in endocytosis (28).
Anisomycin is an antibiotic isolated from Streptomyces
griseolus that inhibits protein synthesis by blocking pepti-
dyl transferase activity in eukaryote ribosomes (29).
Anisomycin is a very useful tool because it selectively
activates kinase cascades in mammalian cells, especially
the MAP kinases (30,31). In this study, we used aniso-
mycin to activate MAP kinases in the absence of ligand
and analyzed the effect of this activation on EGFR inter-
nalization. Interestingly, we observed that anisomycin
treatment induced EGFR endocytosis and that this process
was independent of tyrosine phosphorylation or ubiquitina-
tion. Moreover, preincubation of the cells with SB203580,
a highly specific inhibitor of p38 (32,33), or depletion of
endogenous p38 by small interfering RNAs (siRNAs)
treatment, abolished the anisomycin-induced EGFR inter-
nalization suggesting that this MAP kinase plays an import-
ant role in the regulation of EGFR trafficking.
Results
Anisomycin induces EGFR internalization
To address if the activation of MAP kinases induced by
anisomycin has any effect on EGFR internalization, we
made use of a chimera in which green fluorescent protein
(GFP) has been attached to the carboxyl terminus of human
EGFR (EGFR-GFP). This construct allowed us to easily
visualize EGFR trafficking by immunofluorescence. It has
been previously described that EGFR-GFP biochemical and
cellular properties do not differ from EGFR-wt (34). Figure 1A
s h o w st h a ta ts t a t i o n a r ys t a t e ,m o s to fE G F R - G F Pl o c a l i z e d
at the plasma membrane confirming that the presence of the
GFP did not alter the normal distribution of the protein.
Addition of EGF caused a rapid internalization of the receptor
to endosomal structures as previously described (35).
Interestingly, treatment with anisomycin for short periods
of time also induced endocytosis of EGFR-GFP.
In order to characterize the route followed by EGFR-GFP
after anisomycin treatment, we analyzed the co-localiza-
tion of the receptor with different markers. As shown in
Figure 1B, we found extensive co-localization of EGFR-
GFP with early endosomal markers, such as EEA1 or
internalized transferrin, after incubation with the drug for
15 min. In contrast, no co-localization with the late endo-
somal/lysosomal marker CD63 was observed. Incubation
with EGF for 15 min also caused redistribution of EGFR-
GFP from the plasma membrane to early endosomes (see
Supplementary Material, Figure S1) indicating that both
compounds promote trafficking of EGFR-GFP to the
same compartments.
Next, we analyzed if anisomycin had the same effect on
endogenous EGFR. Control cells or cells treated with
anisomycin or EGF for 15 min were fixed, stained with
an antibody that recognizes the extracellular domain of
EGFR and analyzed by flow cytometry. As shown in
Figure 2, treatment with either anisomycin or EGF caused
a reduction of approximately 70% in the amount of endo-
genous EGFR present at the plasma membrane. This indi-
cated that the effect observed by using EGFR-GFP was
not a consequence of protein over-expression or mistar-
geting of the receptor due to the presence of GFP at the
cytosolic tail, and validates the use of this chimera.
To address if anisomycin causes the internalization of all
cell-surface receptors, we analyzed the effect of the
drug on the distribution of Tac, a cell-surface type 1 trans-
membrane glycoprotein that localizes at the plasma mem-
brane, and TGFbRII, a cell-surface receptor kinase that
requires ligand for internalization. As seen in Figure S2
(Supplementary Material), incubation with anisomycin for
20 min caused a robust internalization of EGFR while hav-
ing no effect on the cell-surface distribution of Tac and
TGFbRII. These data show the specifity of anisomycin for
EGFR trafficking.
Anisomycin promotes endocytosis of EGFR through
clathrin-coated pits
Treatment with anisomycin for short periods of time
revealed that there were no apparent changes in the dis-
tribution of EGFR-GFP throughout the first 5 min of incu-
bation. However, the receptor appeared at punctate
structures following approximately 7 or 8 min of incuba-
tion. Many of these punctate structures contained cla-
thrin and the clathrin adaptor AP2 (Figure 3A) suggesting
that anisomycin induces EGFR internalization through a
clathrin-dependent pathway. To test this possibility, we
examined the effect of over-expressing a dominant-
negative mutant of dynamin2 (Dyn2-K44A-GFP), a
GTPase that is required for the clathrin-dependent inter-
nalization of endocytic receptors. As seen in Figure 3B,
over-expression of Dyn2-K44A-GFP clearly blocked
anisomicyn-induced internalization of EGFR. To further
corroborate these data, we reduced the expression of
endogenous AP2m subunit (m2) by using specific siRNA
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Figure 1: Anisomycin induces internalization of epidermal growth factor receptor-green fluorescent protein (EGFR-GFP). (A)
HeLa cells were transfected with a plasmid encoding EGFR-GFP. Twenty-four hours after transfection, unstimulated (control) cells or cells
treated with EGF (100 ng/mL) or anisomycin (60 mM) for 15 min were fixed and analyzed by confocal microscopy. (B) Cells expressing
EGFR-GFP were treated with anisomycin for 15 min, fixed and stained with the indicated antibodies. For transferrin staining, cells were
incubated with rhodamine transferrin for 15 min at 37  C. In the merge image, EGFR-GFP is in green; EEA1, transferrin and CD63 are in
red and yellow indicates co-localization. Scale bar represents 10 mm.
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reduction in the levels of m2 when compared with cells
transfected with control (non-silencing) siRNA. Levels of
m1 and m3 were monitored as control for the specificity of
the antisense (Figure 3C). HeLa cells depleted of m2
showed very little internalization of transferrin-rhodamine
when compared with control cells, indicating that AP2-
dependent endocytosis is impaired under our experimen-
tal conditions (data not shown). As expected, depletion of
m2 abolished anisomycin-induced internalization of endo-
genous EGFR indicating that the endocytosis is AP2
dependent (Figure 3D,F). Finally, we analyzed the effect
of clathrin siRNA. Figure 3E,F shows that reduction in the
levels of clathrin caused a clear decrease in the amount of
EGFR that was internalized in response to anisomycin. In
contrast, depletion of GGA3, a clathrin adaptor that regu-
lates sorting of proteins at trans Golgi network and endo-
somes, or treatment with non-silencing siRNA, did not
affect EGFR internalization. All together, these data
indicate that anisomycin induces endocytosis of EGFR
through clathrin-coated pits.
Anisomycin-induced internalization of EGFR does not
require tyrosine phosphorylation or ubiquitination
EGF binding induces EGFR dimerization, activation, auto-
phosphorylation of specific tyrosine residues and monoubi-
quitination of the cytosolic tail. It has been proposed that
the recruitment of the endocytic machinery, through inter-
actions with both phosphotyrosines and ubiquitin, plays a
role in the regulation of the receptor endocytosis.
In Figure 4, we used antibodies against specific
phosphotyrosines to follow the activation of the EGFR-
GFP after EGF or anisomycin treatment. As mentioned
previously, the addition of EGF for 15 min induced a
clear redistribution of EGFR-GFP to intracellular vesicles.
The majority of these structures was also labeled with
antibodies against phophotyrosines 845, 1068 and 1086
indicating that EGFR-GFP is activated. In contrast, incuba-
tion with anisomycin caused receptor internalization, but
no activation as no staining for phosphorylated tyrosines
845, 1068 or 1086 was observed (Figure 4A). We also
generated several mutants in which different residues
that are phosphorylated after receptor activation were
mutated to alanines, including Y845, Y974, Y1045,
Y1068, Y1086 and the double mutant S1046/S1047.
Figure S3, Supplementary Material, shows that none of
these mutations affected the normal distribution of the
EGFR-GFP or its response to anisomycin. In addition,
EGFR-GFP immunoprecipitates from HeLa cells treated
with EGF or anisomycin were immunoblotted with the
anti-phosphotyrosine antibody 4G10 confirming that EGF,
but not anisomycin, induced tyrosine phosphorylation of
the receptor (Figure 4B). Anisomycin also failed to stimu-
late ubiquitination of EGFR-GFP as observed by immuno-
precipitation followed by immunoblotting with FK2
antibody (Figure 4C). These results indicate that neither
phosphotyrosines nor ubiquitin seems to be required for
anisomycin-induced EGFR internalization.
Anisomycin induces EGFR degradation
Next, we followed the fate of internalized EGFR after
anisomycin or EGF treatment. HeLa cells were treated
with cycloheximide alone, anisomycin or EGF plus cyclo-
heximide for different periods of time. Western blotting
showed that there was a marked down-regulation of
EGFR after 2 h of incubation with EGF. In contrast, aniso-
mycin caused a much slower degradation of EGFR
(Figure 5A). Quantification of several independent experi-
ments revealed that the differences in the kinetics of
EGFR degradation were more evident after short incuba-
tion times. For example, EGFR levels dropped a 50% after
1 h of incubation with EGF but showed little change with
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Figure 2: Anisomycin promotes endocytosis of endogenous
epidermal growth factor receptor (EGFR). (A) Control HeLa
cells (blue line) or cells treated with EGF (green) or anisomycin
(pink) for 15 min were fixed, and the amount of EGFR present at
the plasma membrane was measured by flow cytometry.
(B) Diagram representing the mean þ SD from three independent
experiments. Percentage of EGFR at the plasma membrane
refers to the fractional reduction of surface receptor in response
to 15-min agonist exposure. For all flow cytometry experiments, a
minimum of 10 000 cells were counted.
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with proteosomal inhibitors such as MG132 almost com-
pletely abolished anisomycin-induced EGFR degradation
but had little effect on EGF-mediated degradation.
Conversely, lysosomal inhibitors blocked EGF but not
anisomycin-mediated degradation (Figure 5C). These
results suggest that anisomycin does not induce delivery
of EGFR to lysosomes. Instead, the receptor could cycle
between plasma membrane and endosomes until it is
degraded most probably through the proteosome,
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Figure 3: Anisomycinpromotesendo-
cytosis of epidermal growth factor
receptor (EGFR) through clathrin-
coated pits. (A) HeLa cells expressing
EGFR-green fluorescent protein (GFP)
were treated with anisomycin (60 mM)f o r
8 min, fixed, stained with the indicated
antibodiesandanalyzedbyconfocalmicro-
scopy.Barrepresents5 mm.(B)HeLacells
transfected with a plasmid encoding the
GFP-tagged form of dynamin 2 K44A
mutant (Dyn2-K44A-GFP) were incubated
for1 honicewithamonoclonalantibodyto
the extracellular domain of EGFR, washed
and allowed to internalize for 20 min at
37  C in the presence of anisomycin
(60 mM). Cells were then fixed, stained
with a Cy3-conjugated donkey anti-mouse
immunoglobulin G and analyzed by confo-
calmicroscopy.Barrepresents 10 mm.(C)
HeLa cells were transfected with small
interferingRNA(siRNA)targetedtocontrol
(non-silencing) or to the m2 subunit of the
AP2complex.Seventy-twohoursafterthe
second round of transfection, equivalent
amounts of homogenate from control and
AP2siRNA-treatedcellsweresubjectedto
SDS–PAGE and immunoblotted using an
antibodytothemsubunitofAP2.Totestthe
specificity of knockdown, lysates were
also blotted to the m subunits of AP1 and
AP3. (D) Cells treated with AP2 siRNA
were left untreated or stimulated with ani-
somycinfor20 min,andcell-surfaceEGFR
was quantified by flow cytometry. (E)
Western blot of totalcellularlevels of CHC
or GGA3 in HeLa cells following transfec-
tion with either control (non-silencing)
siRNA or the specific siRNA. (F) HeLa
cells transfected with either non-targeting
siRNA, siRNA-m2, siRNA-CHC or siRNA-
GGA3 were incubated with anisomycin
for20 minafterwhichtheamountofendo-
genous EGFR internalized was quantified
byflowcytometry.
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cannot be ruled out (36). Consistent with this idea, we
observed a good co-localization between EGFR-GFP and
transferrin up to 1 h following EGFR-GFP internalization
(data not shown).
Anisomycin stimulates early p38 kinase activation
It has been reported that anisomycin is a selective activa-
tor of the MAP kinases (37,38). We examined if this
activation takes place under our experimental conditions
and if it happens quickly enough to justify the early endo-
cytosis observed for EGFR. Total lysates of HeLa cells
stimulated with either EGF or anisomycin at different
times were analyzed by SDS–PAGE and immunobloted
with antibodies against activated p44/42, p38 and JNK.
Total p44/42 was monitored as loading control. As pre-
viously reported, EGF stimulation induced a rapid activa-
tion of three members of the MAP kinase family
(Figure 6). Anisomycin was also able to induce
phosphorylation of both p38 and JNK. In contrast, aniso-
mycin failed to increase p44/42 activation at early time-
points while inducing a very low increase in the levels of
phosphorylated p44/42 after 15 min of incubation. Total
levels of p38 and JNK protein were not altered by aniso-
mycin treatment (data not shown).
Pharmacologic or genetic inhibition of p38 blocks
anisomycin-induced internalization of EGFR
As previously stated, EGFR-GFP appeared in punctated
structures that co-localize with clathrin at approximately
7 min after anisomycin addition. This suggests that the
protein responsible for the endocytosis of EGFR-GFP is
probably activated prior to EGFR-GFP redistribution. The
early activation of p38 induced by anisomycin (Figure 6)
makes this protein an excellent candidate to play a role in
EGFR-GFR internalization. In order to test this possibility,
we used a specific inhibitor for p38. Pyridinyl imidazol,
SB203580, is a highly specific, cell-permeable inhibitor of
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Figure 4: Anisomycin does not induce an increase in tyrosine phosphorylation nor ubiquitination of the epidermal growth
factor receptor (EGFR). (A) Cells transfected with EGFR-green fluorescent protein (GFP) (green) were stimulated with EGF or anisomycin
for 15 min, fixed and stained with specific antibodies against phosphotyrosine 845, 1068 and 1086 (red). Insets show twofold-magnified
views of peripheral cytoplasmic regions. Scale bar represents 10 mm. (B) (C) Whole-cell lysates of HeLa cells expressing EGFR-GFP
prepared from unstimulated cells or cells exposed to EGF or anisomycin for 15 min were immunoprecipitated (IP) with GFP antibodies
and blotted (IB) with anti-phosphotyrosine (4G10) (B) or anti-ubiquitin (FK2) (C) antibodies.
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determine a role for p38 in several biological processes
including UV- and anisomycin-induced c-jun and c-fos
expression (37,39). SB203580 selectively inhibits p38
while having no significant effect on other related kinases
such as ERK and JNK. To block the activity of p38, cells
were treated with 10 mM SB203580 for 30 min at 37  C
before being exposed to anisomycin for 15 min. As shown
in Figure 7A, treatment with SB203580 dramatically
decreased the internalization of EGFR-GFP induced by
anisomycin, suggesting that p38 activation is necessary
for this process. Interestingly, treatment with AG1478, a
selective inhibitor of EGFR tyrosine kinase, had no effect
on EGFR-GFP endocytosis, further confirming that phos-
phorylation of EGFR tyrosines is not required for anisomy-
cin-induced EGFR internalization.
Next, we determined if inhibition of p38 by SB203580 had
a non-specific effect on clathrin-mediated endocytosis.
Figure 7B shows that preincubation with SB203580
blocked anisomycin-induced internalization of EGFR-GFP
without affecting transferrin endocytosis. This result indi-
cated that activation of p38 does not play a general role in
clathrin-mediated internalization but it is required for
down-regulation of specific receptors.
The requirement of p38 MAPK activation for anisomycin-
dependent EGFR internalization was further analyzed by
flow cytometry. FACS analysis of the EGFR surface
expression indicated that preincubation with SB203580
caused a 2.5 fold reduction in the amount of endogenous
EGFR internalized after 15 min of anisomycin stimulation
(Figure 7C,D). Treatment with dimethyl sulphoxide
(DMSO) had no effect on EGFR endocytosis (data not
shown).
To corroborate that p38 is required for anisomycin-induced
internalization of EGFR, we employed genetic means to
selectively deplete endogenous p38. To do so, HeLa cells
were transfected either with a pool of siRNAs targeting
p38a (siRNA-p38a), p38b (siRNA-p38b)o rac o m b i n a t i o no f
both (siRNA-p38a þ b). As seen in Figure 8, expression of
p38a,b u tn o tt h a to fp 3 8 b, was abrogated in siRNA-p38a
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densities of the corresponding EGFR bands from three independ-
ent experiments. (C) Cells were preincubated with MG132
(10 mM) or bafilomycin (0.25 mM) and then treated with EGF or
anisomycin. Three hours after the treatment, cells were har-
vested and immunoblotted with anti-EGFR.
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Figure 6: Time–course analysis of the effect of anisomycin
on mitogen-activated protein kinase activity. After treatment
with epidermal growth factor (EGF) or anisomycin, cell lysates
were prepared and subjected to SDS–PAGE followed by Western
blotting analysis with the indicated antibodies.
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692 Traffic 2006; 7: 686–698cells, while an inhibition in the expression of p38b, but not
p38a, was seen in siRNA-p38b cells. Transfection of
siRNA-p38a þb caused a significant reduction in the levels
of both p38a and p38b, while treatment with a control
non-targeting siRNA did not affect the expression of either
of the two isoforms. Interestingly, abrogation of expres-
sion of either p38a or p38b reduced the efficiency of
EGFR internalization after anisomycin treatment
(Figure 8B). This reduction was much more robust in
siRNA-p38a þ b cells, where only a 10% EGFR internal-
ization was observed after incubation with anisomycin for
15 min. All together, these results indicate that both p38a
and p38b might act synergistically in the regulation of
EGFR trafficking.
p38 activation is also required for endocytosis of
EGFR induced by UV radiation
It has been reported that UV radiation can induce internal-
ization of EGFR independent of its phosphorylation or RTK
activation. The mechanism that mediates this process has
not been characterized although it has been suggested
that direct absorption of UV energy might induce a con-
formational change of EGFR (40,41). The fact that p38 can
be activated by a variety of stress signals, including UV
radiation, suggested that this protein could be involved in
the UV-induced internalization of EGFR. Figure 9 shows
that after UV radiation (200 J/m
2) an extensive EGFR-GFP
internalization, comparable with that seen after EGF or
anisomycin stimulation, was observed. As expected, addi-
tion of SB203580 to the cells 30 min prior to UV radiation
inhibited EGFR-GFP internalization which confirmed our
hypothesis that p38 plays an important role in UV-induced
endocytosis of EGFR.
Discussion
We have shown that activation of the stress-induced p38
MAP kinase by anisomycin induces a rapid internalization
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dent of RTK activity and monoubiquitination of the cyto-
solic tail indicating that EGF and anisomycin employ
different mechanisms to promote internalization. The
lack of ubiquitination prevented the delivery of EGFR to
lysosomes for degradation. This observation is in agree-
ment with recent reports that found that ubiquitination of
EGFR is required for interaction with the mutivesicular
bodies-sorting machinery (42,43).
p38 was originally identified as a kinase phosphorylated in
response to endocytic lipopolysacharides (44,45). Later, it
was found that p38 activity is also up-regulated when cells
are exposed to a variety of stimuli including certain growth
factors, proinflammatory cytokines (46–48) and different
forms of environmental stress such as UV light (35,49),
heat (32) and osmotic shock (32,45,46). To date, four
members of the p38 group of MAP kinases have been
characterized, including p38a (50), p38b (51), p38g (52,53)
and p38d (51). SB203580 is a selective inhibitor for both,
p38a and b, but has no effect on the activity of the g and d
isoforms. The inhibition of the anisomycin-induced EGFR
internalization observed in the presence of SB203580
strongly suggests the involvement of p38a and/or p38b
in this process. The additive effect of p38a and p38b
silencing on EGFR internalization after anisomycin treat-
ment corroborate that both isoforms likely play an impor-
tant role in the regulation of EGFR trafficking. It is
important to note that, while inhibition of p38 activation
clearly prevented EGFR entry into the cells, no effect on
transferrin internalization was observed, indicating that
SB203580 does not cause a general block of clathrin-
mediated endocytosis.
Recently, it has been shown that exposure of cells to UV
radiation also induces internalization of EGFR (40), but the
precise mechanism that controls this process remains
unknown. Significantly, there are several similarities
between UV-induced and anisomycin-induced EGFR endo-
cytosis. For example, in both cases, EGFR internalization
is processed by clathrin-coated pits, is independent of RTK
activity or autophosphorylation, does not require receptor
ubiquitination and does not result in lysosomal degradation
of the receptor (41,54,36). In this paper, we show that
activation of p38 is involved in the UV-induced internaliza-
tion of EGFR, suggesting that the regulation of EGFR
endocytosis by p38 can occur under physiological condi-
tions. It has been shown that EGFR is involved in cell
proliferation, survival and tumorogenesis and that prevent-
ing EGFR down-regulation facilitates cell transformation.
Therefore, external stimuli that cause p38 activation could
control the accessibility of EGFR at the plasma membrane
preventing that way cell proliferation and survival under
stress conditions.
How does p38 promote the internalization of EGFR? There
is growing evidence showing that p38 plays an important
role in numerous biological processes including inflamma-
tion (55,56), development (57,58), cell death (59,60), cell
cycle (61), cardiomyocyte hypertrophy (62), cell differen-
tiation (63,64), senescence (65) and tumorogenesis (66).
Recently, it has been suggested that p38 might also parti-
cipate in the regulation of endocytic trafficking. Cavalli
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Figure 8: Effect of silencing of p38a and p38b on anisomycin-
induced epidermal growth factor receptor (EGFR) internaliza-
tion. (A) HeLa cells were treated with small interfering RNA
(siRNA) targeted to p38a (siRNA-p38a), p38b (siRNA-p38b)o r
both (siRNA-p38a þ b). After two consecutive transfections with
siRNA, the expression of the two isoforms was assessed
by Western blotting. (B) HeLa cells transfected with either non-
targeting siRNA, siRNA-p38a, siRNA-p38b or siRNA-p38a þ b
were incubated with anisomycin for 15 min after which the
amount of endogenous EGFR remained at the plasma membrane
was quantified by flow cytometry.
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and activate guanyl-nucleotide dissociation inhibitor (GDI),
a key regulator of the Rab cycle. Rab proteins are small
monomeric GTPases with molecular masses in the
20–30 kDa range (68). Multiple Rabs have been shown to
participate in the formation, fusion and movement of vesi-
cular traffic intermediaries between different membrane
compartments of the cell. Rabs function as molecular
switches by cycling between two interconvertible forms,
a cytosolic GDP-bound (inactive) form and a membrane
associated GTP-bound (active) form. In addition, Rabs
also cycle between membrane-bound and cytosolic states,
and this cycling is regulated by GDI (69).
Rab 5 in particular seems to play an important role in the
trafficking of EGFR. Several studies have established that
activated EGFR modulates the GTPase activity of Rab5 by
targeting either GTPase-activating proteins, such as RN-Tre
(70), or GTP exchange factors, such as RIN1 (71). The activ-
ationofRab5throughEGFRortheexpressionofconstitutively
active mutants of Rab5 stimulates both the internalization
and degradation of activated EGFR. In contrast, dominant
negative Rab5 blocks EGF-stimulated receptor-mediated
and fluid-phase endocytosis (72). Therefore, p38 could pro-
mote EGFR endocytosis by stimulating the activity of GDI in
extracting Rab5 from the endosomal membranes and form-
ing cytosolic GDI-Rab5 complex. Interestingly, GDI-Rab5 has
been identified as a component of the machinery controlling
clathrin-coated endocytic vesicle formation (73). In addition,
GDI might facilitate the delivery of Rab5 to specific regions
of the plasma membrane facilitating the interaction with
cytoskeleton or specific effectors. In agreement with this
idea, Huang et al. (74) have shown that the activation
of p38 induced by metabotropic glutamate receptor agonists
accelerates loss of surface amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptors by stimulating the
formation of GDI-Rab5 complexes.
We cannot discard the possibility that activation of p38
could also affect EGFR recycling. Recent evidence sug-
gests that p38 can be recruited to endosomes (28) and
regulates endosomal Rab5 effectors such as EEA1 (75).
p38 also seems to play a negative regulatory role in
Mycobacterium tuberculosis infection by modulating the
recruitment of EEA1 to phagosomes and inhibiting that
way phagosome maturation (76). This involvement may
reflect a more general role for p38 in the regulation of
intracellular trafficking. While further studies will be
required to assess the specific mechanisms used by p38
to regulate EGFR internalization, our results strengthen
the idea that there is a clear intercommunication between
signaling and intracellular trafficking and suggest that p38
is a key player in this process.
Materials and Methods
Antibodies and reagents
The following commercial antibodies were used: mouse monoclonal anti-
ubiquitin (FK2; Affiniti, Devon, UK), mouse monoclonal anti-EEA1, mouse
monoclonal anti-CHC and mouse monoclonal anti-GGA3 (BD Transduction
Laboratories, San Jose, CA, USA), mouse monoclonal anti-human TGFbRII
(R&D Systems Inc., Minneapolis, MN, USA), mouse monoclonal to
a-adaptin (AP-6; Affinity Bioreagents, Golden, CO, USA), mouse monoclo-
nal anti-CD63 (H5C6; BD Pharmigen, San Jose, CA, USA), mouse
phosphotyrosine antibody (clone 4G10; Upstate Biotechnology, Lake
Placid, NY, USA), rabbit anti-GFP (MBL International, Woburn, MA, USA),
mouse monoclonal and rat monoclonal anti-EGF receptor (ab3103 and
ICR10; Abcam, Cambridge, MA, USA). Rabbit polyclonal antibodies against
p38, phospho-p38, p44/42, phospho-p44/42, phospho-JNK, EGF-receptor,
phospho-EGF receptor (Tyr845), phospho-EGF receptor (Tyr1068) and
phospho-EGF receptor (Tyr1086) were obtained from Cell Signaling
Technology (Beverly, MA, USA). Rabbit polyclonal antibodies to m1, m2
and m3 were the kind gift of JS. Bonifacino (NIH, Bethesda, MD, USA).
Anisomycin, EGF, SB203580, AG1478, MG132, bafilomycin A1, ubiquitin
aldehyde, mammalian phosphatase inhibitor cocktail and NP40 were
obtained from Sigma (St. Louis, MO, USA). Rhodamine-transferrin was
supplied by Molecular Probes (Eugene, OR, USA).
Control UV 30 min SB203580 + UV 30 min
Figure 9: SB203580 inhibits UV-mediated internalization of epidermal growth factor receptor (EGFR). Control cells or cells
preincubated with SB203580 for 30 min were irradiated with UV light (200 J/m
2) and chased at 37  C for 30 min. Cells were fixed and
the distribution of EGFR-green fluorescent protein was analyzed by confocal microscopy. Scale bar represents 10 mm.
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Cloning and characterization of the EGFR-GFP chimera has been previously
described (34). Mutations of residues in the cytosolic tail of EGFR-GFP
were introduced using the QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA). The GFP-tagged dynamin2 K44A construct
was a gift from M. McNiven (Mayo Clinic, Rochester, MN, USA).
siRNA
RNAi of CHC, GGA3 and the m subunit of the AP2 complex was performed
using siRNAs to the following human target sequences:
UAAUCCAAUUCGAAGACCAAUU for CHC, GUGGAUGCCUUUCGGGUCA
for m2 and AAAAACGGCUUCCGCAUCCUC for GGA3 (Dharmacon
Research, Lafayette, CO). Heterogeneous duplex siRNA pool against p38
MAP kinase and p38 MAP kinase b were obtained from Cell Signaling
Technology and Dharmacon, respectively. For each siRNA, two consecu-
tive transfections every 72 h were carried out in HeLa cells according to
the manufacturer’s instructions.
Transfection and immunofluorescence microscopy
HeLa cells were transfected with a plasmid encoding EGFR-GFP by using
FuGENE-6 (Roche Diagnostics, Indianapolis, IN, USA). For immunofluores-
cence, transfected HeLa cells were grown on coverslips. Twenty-four
hours after transfection, the cells were maintained in serum-free medium
for 6–8 h, stimulated with EGF (100 ng/mL) or anisomycin (60 mM) for
15 min and fixed in methanol/acetone (1:1, v/v) for 10 min at  20  C.
Coverslips were mounted onto glass slides with Fluoromount G
(Southern Biotechnology Associates, Birmingham, AL, USA).
Fluorescence images were acquired on an LSM 510 confocal microscope
(Carl Zeiss, Thornwood, NY, USA).
To examine the co-localization of EGFR-GFP with endosomal markers,
incubation with primary antibodies diluted in PBS, 0.1% (wt/vol) saponin
and 0.1% BSA, was carried out for 1 h at room temperature. Unbound
antibodies were removed by rinsing with PBS for 5 min, and cells were
subsequently incubated with a secondary antibody (Cy3-conjugated don-
key anti-rabbit or anti-mouse Ig) diluted in PBS, 0.1% (wt/vol) saponin and
0.1% BSA, for 30–60 min at room temperature. After a final rinse with
PBS, coverslips were mounted onto glass slides with Fluoromount G and
analyzed by confocal microscopy.
Treatments with SB203580 or AG1478 were carried out by incubation of
the cells with the inhibitors for 30 min prior to anisomycin stimulation. Cells
were exposed to UV radiation in a UV Stratalinker 2400 (Stratagene).
Immunoprecipitation and immunoblot
HeLa cells were starved for 8 h in serum-free medium and then stimulated
with EGF (100 ng/mL) or anisomycin (60 mM) for 15 min. The cells were
then washed with ice-cold PBS and lysed for 15 min in lysis buffer (25 mM
Tris–Cl, pH 7.4, 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid,
20 mM NaF, 0.5% NP40) supplemented with protease, tyrosine phospha-
tase and ubiquitin hydrolase inhibitors. The lysate was precleared by cen-
trifugation and incubated with 5 mL of anti-GFP or a non-specific antibody
and protein G-Sepharose (Amersham Biosciences, Piscataway, NJ).
Immunoprecipitates were collected, washed six times with 1 mL of lysis
buffer supplemented with phosphatase inhibitors and analyzed by SDS–
PAGE under reducing conditions.
Immunoblotting was carried out according to standard procedures.
Proteins were separated by SDS–PAGE and transferred to nitrocellulose.
The membrane was then blocked with PBS/0.05% Tween-20/10% BSA
and incubated with the various antibodies. Enhanced chemiluminescence
reagent (Amersham Biosciences) was used for detection.
Degradation and MAP kinase activation assays
HeLa cells were serum starved for 8 h and stimulated with EGF (100 ng/
mL) or anisomycin (60 mM) for the indicated times. For degradation assays,
total cell lysates were subjected to immunoblotting with antibodies against
EGFR. The amounts of EGFR were quantified at each time-point by using
the public domain NIH Image program (1.6–2) and are represented as the
percentage of remaining EGFR in comparison with unstimulated cells in
the same experiment. The activation of p44/42, JNK and p38 was deter-
mined by Western blotting with antibodies specific for phosphorylated,
activated forms of these kinases.
Quantitative internalization assay
HeLa cells were grown to 90% confluence. Following serum starvation
for 4–5 h, the cells were harvested in Cellstripper
TM
solution (Mediatech,
Inc., Herdon, VA), washed once with cold PBS and incubated with DMSO
or SB203580 (10 mM) at 4  C for 30 min. The cells were then incubated
with EGF (100 ng/mL) or anisomycin (10 mM) for the indicated times at
37  C, and then placed on ice to stop internalization. The cells were fixed
with 2% paraformaldehyde, incubated with the FITC-conjugated anti-EGFR
antibody for 45 min on ice, washed and analyzed by the FACS-Calibur
using CELLQUEST software (BD Bioscience, San Jose, CA). Amounts
of EGFR remaining on the cell surface were defined as the specific
fluorescence value, which was calculated after subtracting background
(fluorescence of non-stained cells). Percent internalization was calculated
where the specific mean fluorescence value of cells incubated at 37  C
with SB203580 was treated as 100%.
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Supplementary Material
Figure S1. EGFR-GFP redistributes from the plasma membrane to early
endosomes after EGF stimulation. HeLa cells were transfected with a
plasmid encoding EGFR-GFP. Transfected cells were incubated with EGF
(100 ng/mL) for 15 min, fixed, permeabilized, immunostained with the
indicated antibodies and examined by confocal fluorescence microscopy.
For transferrin staining, cells were incubated with rhodamine-transferrin for
15 min at 37  C. EGFR-GFP is in green; EEA1, transferrin and CD63 are in
red and yellow indicates co-localization. Scale bar represents 10 mm.
Figure S2. Anisomycin has no effect on the distribution of Tac and
TGFbRII. (A) HeLa cells expressing EGFR-GFP or Tac were left untreated
or stimulated with anisomycin for 20 min. Cells were then fixed and
analyzed by confocal microscopy. Bar represents 10 mm. (B) Cell surface
levels of EGFR or TGFbRII were quantified by flow cytometry in unstimu-
lated cells or cells exposed to anisomycin for 20 min. For detection of
TGFbRII, HeLa cells were transiently transfected with a plasmid encoding
human TGFbRII.
Figure S3. Anisomycin-induced internalization of EGFR-GFP was not
affected by mutation of specific carboxy-terminal tyrosine residues to
alanines. Wild-type EGFR-GFP or EGFR-GFP carrying the indicated muta-
tions were transiently expressed in HeLa cells. Twenty-four hours after
transfection, cells were either left untreated, or incubated with anisomycin
for 15 min, fixed and analyzed by confocal microscopy. Scale bar repre-
sents 10 mm.
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